CD40 and familial pancreatic carcinoma: Anti-CD40 antibody, for example, has been shown to re-activate macrophages in pancreatic cancer mouse models, leading to the recruitment of anti-tumor M1 macrophages to the tumor site, depletion of tumor stroma and consequently to increased efficacy of chemotherapeutic agents such as gemcitabine [44].